An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

H. Lundbeck A/S15 enrolled

Overview

To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.

The study comprised 5 cohorts (Cohorts 1 to 5), with each cohort consisting of 3 patients with Parkinson's disease (men and/or women). Each patient will be treated for 3 or 4 days, with increasing dose each day. Dosing regimen will be decided at a dosing conferences. Dose levels can be increased, maintained or reduced both between cohorts but also within same cohort. The results are presented by dose level and reflect the actual doses administered. A follow-up safety visit was scheduled approximately 7 days after the last dose of IMP.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Parkinson Disease

Interventions

0.04 mg Lu AE04621DRUG

0.04 mg dose group

0.08 mg Lu AE04621DRUG

0.08mg dose group

0.2 mg Lu AE04621DRUG

0.2 mg dose group

0.4 mg Lu AE04621

Eligibility

Sex: ALLMin age: 45 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient is diagnosed with idiopathic Parkinson Disease (consistent with the UK Parkinson's Disease Society Brain Bank Criteria for the Diagnosis of PD). * The patient's Hoehn and Yahr Staging score is ≤ 3 in the "ON" state. * The patient experiences motor fluctuations with at least 2.5 hours of "OFF" periods in the awake time and has predictable morning "OFF" episodes, which have been consistent within the past 4 weeks. * The patient currently has a good response to L-DOPA and has been receiving a stable dose of L-DOPA (≥3 doses per day of standard L-DOPA or ≥3 doses per day of Carbidopa and L-DOPA, Extended-Release Capsules) during at least four weeks prior to screening. Exclusion Criteria: * The patient has cognitive impairment, defined as a Mini Mental State Examination(MMSE) score ≤ 26 at the Screening Visit. * The patient has severe disabling dyskinesia * The patient takes or has taken disallowed recent or concomitant medication (CYP2D6 inhibitors, CYP 3A4 substrate, Dopamine agonists, 5 HT3 antagonists, Anti-viral (Amantadine)) Other protocol defined inclusion and exclusion criteria may apply

Locations (4)

US1251

Hallandale, Florida, United States

US1126

Orlando, Florida, United States

US1352

Chicago, Illinois, United States

US1084

Detroit, Michigan, United States

Outcomes

Primary Outcomes

Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG)

Number of patients with an adverse event

Time frame: Baseline to day 11

Area Under the Plasma Concentration-time Curve (AUC(0-24 Hours)) for Lu AE04621

Time frame: From dosing to up to 24 hours after dosing

Maximum Observed Concentration (Cmax) for Lu AE04621

Time frame: From dosing to up to 24 hours after dosing

Apparent Elimination Half-life of Lu AE04621 in Plasma (t½)

Time frame: From dosing to up to 24 hours after dosing

Time to Onset of "ON" Time After Lu AE04621 Administration

"ON" state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to "ON" and "OFF" state. "OFF" state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.

Time frame: From dosing to 90 minutes after dosing

Duration of "ON" Time

"ON" state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to "ON" and "OFF" state. "OFF" state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia. Outcome measured in minutes. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON' following administration of Lu AE04621.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.